T. Rowe Price Associates’s Enliven Therapeutics ELVN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $10.6M | Buy |
528,250
+512,090
| +3,169% | +$10.3M | ﹤0.01% | 1101 |
|
|
2025
Q1 | $319K | Buy |
16,160
+2,533
| +19% | +$50K | ﹤0.01% | 2438 |
|
|
2024
Q4 | $307K | Buy |
13,627
+1,980
| +17% | +$44.6K | ﹤0.01% | 2490 |
|
|
2024
Q3 | $298K | Buy |
11,647
+440
| +4% | +$11.3K | ﹤0.01% | 2479 |
|
|
2024
Q2 | $262K | Buy |
+11,207
| New | +$262K | ﹤0.01% | 2485 |
|